Acceleron Pharma Inc. Stock News

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Acceleron Pharma Inc. (NASDAQ: XLRN) to Merck & Co., Inc. for $180.00 per share in

MILWAUKEE, Sept. 30, 2021 /PRNewswire/ -- Ademi LLP is investigating Acceleron (Nasdaq: XLRN), for possible breaches of fiduciary duty and other violations of law in its transaction with Merck.

Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs heart.

Putting all the speculations at bay, Merck & Co Inc (NYSE: MRK) has agreed to acquire Acceleron Pharma Inc (NASDAQ: XLRN) for $180 per share in cash for an approximate total equity value of $11.5

Merck will buy Acceleron Pharma for $180 per share, snapping up Acceleron's late-stage cardiovascular drug in the process. CNBC's Meg Tirrell reports.

Merck & Co will buy drugmaker Acceleron Pharma Inc for about $11.5 billion, the companies said on Thursday, as the U.S. pharmaceutical giant looks to beef up its portfolio with drugs for rare diseases

Acceleron (XLRN) up on rumors of a potential acquisition by a pharma giant for $11 billion or $180 per share.

The Wall Street Journal reported that Merck & Co Inc (NYSE: MRK) is in advanced talks to acquire Acceleron Pharma Inc (NASDAQ: XLRN), citing people familiar with the matter. The deal for Acceler

Merck is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant's rare-disease business.

Merck & Co. is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant's rare-disease business.

Bristol-Myers Squibb Co. ( BMY , Financial) is the odds-on favorite to acquire Acceleron Pharma Inc. ( XLRN , Financial) and the rights to its two promising drugs, reported Bloomberg.

Merck & Co is in advanced talks to acquire drugmaker Acceleron Pharma Inc, the Wall Street Journal reported https://www.wsj.com/articles/merck-nears-deal-to-acquire-acceleron-pharma-11632778405?mod=la

Shares of Acceleron Pharma Inc. XLRN, +4.89% gained 3.9% in premarket trading on Monday after Bloomberg reported Friday that an unnamed buyer is considering spending $11 billion to buy the company. Ac

Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is potentially in advanced talks for an $11 billi

Buyout rumors are swirling around this mid-cap biotech company.